Back to search
FDAFDA · Food and drugs·Recall number D-0689-2026

CLEVIPREX (clevidipine injectable emulsion) 50 mg/100 mL (0.5 mg/mL), 10 Single Use Vials, Rx Only, Manufactured for: Chiesi USA, Inc., Cary, NC 27518, by Fresenius Kabi, Graz, Austria, NDC 10122-611-10.

Published July 22, 2026 · Recall initiated: July 6, 2026

Summary

FDA records drug Class II recall D-0689-2026, published July 22, 2026 and initiated July 6, 2026. Recalling firm: Chiesi USA, Inc.; Status: Ongoing; Reported quantity: 44280 vials; Lot: Lot #: 1239521, 1237454, Exp. Date 10/2027. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Lack of Assurance of Sterility

What to do

Voluntary: Firm initiated · Letter

Get an email if CLEVIPREX has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
CLEVIPREX
Manufacturer
Chiesi USA, Inc.
Distributor
Nationwide within the United States
Lot
Lot #: 1239521, 1237454, Exp. Date 10/2027
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was CLEVIPREX (clevidipine injectable emulsion) 50 mg/100 mL (0.5 mg/mL), 10 Single Use Vials, Rx Only, Manufactured for: Chiesi USA, Inc., Cary, NC 27518, by Fresenius Kabi, Graz, Austria, NDC 10122-611-10. recalled?

Yes. FDA published recall D-0689-2026 on July 22, 2026. Reported hazard: Lack of Assurance of Sterility

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: CLEVIPREX.